

## Starpharma to present DEP<sup>®</sup> platform at CRS Annual Meeting

**Melbourne, Australia; 27 July 2021: Starpharma** (ASX: SPL, OTCQX: SPHRY) today announces that it has been invited to present at the prestigious Controlled Release Society (CRS) Virtual Annual Meeting. Starpharma will be represented by its VP of Research, Dr David Owen, who will present an overview of the [DEP<sup>®</sup> platform](#) and its benefits as part of the ‘**Success Stories from Bench to Trials to Market**’.

The CRS Annual Meeting showcases outstanding research, contributions, and commitment to drug delivery science and technology. It also provides networking opportunities with senior scientific and commercial executives from many major international pharmaceutical companies. This year’s meeting will take place online from 25-29 July 2021 with an estimated 1,300+ global attendees including senior development, licensing and regulatory executives from global pharma and biotech companies, including AstraZeneca, BMS, Roche Pharma, Merck, Novartis, Sanofi, World Health Organisation, US FDA, and Janssen Pharmaceutics (J&J).

Dr Owen’s presentation, “DEP<sup>®</sup> Drug Delivery - Application for the development of dendrimer-based chemo and radio therapeutics” is scheduled at 10:24am EDT 27 July 2021, and includes:

- Overview of Starpharma’s three Phase 2 clinical-stage assets: DEP<sup>®</sup> docetaxel, DEP<sup>®</sup> cabazitaxel, and DEP<sup>®</sup> irinotecan.
- Performance benefits and broad applicability of DEP<sup>®</sup> technology including in combination therapies and new technology
- Commercial benefits of Starpharma’s DEP<sup>®</sup> technology in partnered programs, including AZD0466, which AstraZeneca recently advanced and [expanded](#) into a global Phase 1/2 study.
- Snapshot of the Company’s preclinical DEP<sup>®</sup> pipeline, including DEP<sup>®</sup> chemotherapeutic, DEP<sup>®</sup> radiopharmaceutical, and DEP<sup>®</sup> antibody drug conjugates (ADCs) products.
- Further detail on DEP<sup>®</sup> ADCs, which have the potential to overcome certain challenges faced by existing ADC approaches.

A copy of the presentation will be made available on Starpharma’s website at [www.starpharma.com](http://www.starpharma.com).

In addition to Dr Owen’s presentation, Dr Orlagh Feeney of Monash Institute of Pharmaceutical Sciences (MIPS), will present new data on AZD0466 generated under a research collaboration between AstraZeneca, Starpharma, and MIPS. Dr Feeney’s presentation will highlight impressive efficacy data of AZD0466 in a Lymphoma model, demonstrating the potential role of AZD0466 in treating lymphoma.

## Starpharma's DEP® Platform

Starpharma's dendrimers can be used to enhance the properties of other drugs. The approach is known as "drug delivery" because it is about working to ensure that the drug is delivered to the right part of the body at the right time. Starpharma's dendrimer drug delivery technology is known as DEP®.

Starpharma uses DEP® both in its own drug development pipeline and with partners. The most advanced DEP® products in Starpharma's pipeline are DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, which are in Phase 2 clinical trials.

Benefits of DEP® dendrimer drug delivery include<sup>^</sup>:

- Improving efficacy
- Reducing toxic side effects of existing drugs
- Extending the duration of activity of the drug in the body
- Targeting drugs to Organs, Tissues, or Molecular Receptors
- Increasing Solubility
- Broad applicability and flexibility with new research areas including radiotheranostics and antibody drug conjugates (ADCs)

Starpharma's DEP® platform provides exceptional optionality and leverage given that the DEP® technology can be licensed multiple times, and licences are structured to enable multiple partnered DEP® programs to run in parallel. Starpharma now has DEP® programs with multiple large pharma companies, including AstraZeneca, Merck, Chase Sun, and other undisclosed partnerships

<sup>^</sup>Clinical studies have demonstrated reduction in important side effects with DEP® including bone marrow toxicity, anaphylaxis, oedema, and hair-loss. Multiple preclinical studies have established improved efficacy, survival, and safety with DEP® with many different drugs

---

## About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](https://www.starpharma.com) | [Twitter](#) | [LinkedIn](#)

---

**Media: Sumit Media**

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

**Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

**Disclosure**

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

**Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.